Background: Hypothermic Machine Perfusion (HMP) of kidneys preserves organ integrity better and longer than Simple Cold Storage (SCS). Interest in liver HMP is increasing but there are no data on the capacity of HMP to preserve the morphology of human livers for prolonged periods. We developed an HMP device for human livers with dual arterial/portal perfusion and separate pressure/flow controls. Methods: After ethical and Belgian Liver Intestine Committee (BLIC) approval, 6 human livers considered potentially transplantable but discarded due to mild changes, recipient contra-indication and eventually failed ET-reallocation were machine-perfused during 24hrs at 4-6°C using preservation solution KPS-1 ™ . Metabolic/biochemical/hemodynamics parameters and standard/electron microscopy were assessed. Results: During HMP, pO2 decreased whereas pCO2 increased, suggestive of initial aerobic metabolism rapidly replaced by anaerobic metabolism as indicated by rising lactate and decreasing pH. AST in perfusate progressively increased: 538±484, 631±515, 927±657 and 945±573 IU/L at 30min, 1, 6 and 24hrs. Arterial and venous vascular resistances decreased from 1.29±0.67 and 0.25±0.30 (at the start) to 0.52±0.47 and 0.13±0.13 mmHg/min/ml after 24hrs HMP (p=0.13 and p=1, respectively). On detailed light/electron microscopic examination after 24hrs HMP, morphology/architecture was wellpreserved. Some sinusoidal dilatation and enlargement of Disse space were seen. Hepatocytes, Kupffer and sinusoidal cells ultrastucture was wellmaintained. Anoxic vacuoles were seen in some hepatocytes. Occasionally, hepatocytes contained slightly swollen mitochondria with less electron-dense matrix (reversible changes) or more rarely, flocculent densities (irreversible changes). Other cytoplasmic organelles appeared normal. Conclusion: This study shows -for the first time-that HMP is capable to preserve the morphology and cellular integrity of human livers for prolonged periods (>24hrs). Randomized control trials of transplantation of machineperfused livers are planned to determine the added value of HMP compared to SCS to preserve human livers. Antecedents: Hepatic ischemia reperfusion injury contributes to the initial poor function or primary non-function after transplantation. This is due to the cold preservation, rewarming and reperfusion, respectively. We evaluated the benefits of using a new rinse solution for flushing liver grafts before reperfusion. Experimental: Sprague-Dawley rats (180-200 g; n= 6 for each group), were classified as follows: Group 1 (controls) = Livers preserved in UW solution (24 hours; 4 C) were flushed with Ringer lactate solution (at room temperature)and then subjected to 2 h-reperfusion at 37 C using an isolated perfused liver model; Group 2 (washout solution) = Same as 1 but the liver grafts were flushed (at room temperature) with the new rinse solution composed by CaCl2.2H2O (1.3 mM), KH2PO4 (5 mM), NaH2PO4 (20 mM), MgSO4.7H2O (5 mM), lactobionate (100 mM) and rafinose (30 mM) at pH=7.4; Group 3 = Same as 2 but with polyethyleneglycol-35 (PEG35) addition at 5g/L and Group 4 = Same as 3 but with PEG35 addition at 1g/L. Liver injury (AST/ALT) and function (Bile,%BSP, vascular resistance) were measured and correlated with activated adenosine monophosphate protein kinase (AMPK) and hemeoxygenase-1 (HO-1) and HSP70 activities, oxidative stress (MDA) and nitric oxide (NO). Results: The use of this graft washout solution prevented liver injury (AST/ALT) and ameliorated hepatic function (bile production, vascular resistance) when compared to those washed with RLS, only. This was accompanied by decreases in GLDH levels (mitochondrial lesion) and oxidative stress. Graft washout benefits were associated with increases in NO (e-NOS activation); as well as the induction of cytoprotective factors such as AMPK and HO-1 and HSP70, respectively. Conclusion: This new "washout" solution containing PEG35 protects the liver grafts against reperfusion injury.
RO-076 LIVER WASHOUT PRECONDITIONING: A USEFUL TOOL TO PROTECT THE GRAFT AGAINST REPERFUSION INJURY
Antecedents: Hepatic ischemia reperfusion injury contributes to the initial poor function or primary non-function after transplantation. This is due to the cold preservation, rewarming and reperfusion, respectively. We evaluated the benefits of using a new rinse solution for flushing liver grafts before reperfusion. Experimental: Sprague-Dawley rats (180-200 g; n= 6 for each group), were classified as follows: Group 1 (controls) = Livers preserved in UW solution (24 hours; 4 C) were flushed with Ringer lactate solution (at room temperature)and then subjected to 2 h-reperfusion at 37 C using an isolated perfused liver model; Group 2 (washout solution) = Same as 1 but the liver grafts were flushed (at room temperature) with the new rinse solution composed by CaCl2.2H2O (1.3 mM), KH2PO4 (5 mM), NaH2PO4 (20 mM), MgSO4.7H2O (5 mM), lactobionate (100 mM) and rafinose (30 mM) at pH=7.4; Group 3 = Same as 2 but with polyethyleneglycol-35 (PEG35) addition at 5g/L and Group 4 = Same as 3 but with PEG35 addition at 1g/L. Liver injury (AST/ALT) and function (Bile,%BSP, vascular resistance) were measured and correlated with activated adenosine monophosphate protein kinase (AMPK) and hemeoxygenase-1 (HO-1) and HSP70 activities, oxidative stress (MDA) and nitric oxide (NO). Results: The use of this graft washout solution prevented liver injury (AST/ALT) and ameliorated hepatic function (bile production, vascular resistance) when compared to those washed with RLS, only. This was accompanied by decreases in GLDH levels (mitochondrial lesion) and oxidative stress. Graft washout benefits were associated with increases in NO (e-NOS activation); as well as the induction of cytoprotective factors such as AMPK and HO-1 and HSP70, respectively. Conclusion: This new "washout" solution containing PEG35 protects the liver grafts against reperfusion injury.
RO-077 HYPOTERMIC MACHINE PERFUSION (HMP) VERSUS STATIC COLD STORAGE (CS) IN KIDNEY ALLOGRAFT PRESERVATION. PROSPECTIVE CASE-CONTROL TRIAL
Annalisa Amaduzzi, Fausto Catena, Giulia Montori, Matteo Ravaioli, Antonio Pinna. Multiorgan Transplant Centre, Sant'Orsola Hospital, Bologna, Italy Background: The shortage of organ availability for transplant has led to an increased use of expanded criteria donors grafts to enlarge the donors pool. It has been suggested that HMP may improve early outcome after transplantation of kidneys donated after cardiac death, but no prospective case control trial have been reported in brain death donor. Aim of the present trial is to identify the most effective preserving method comparing in a randomized case-control trial hypothermic machine perfusion with the current standard of static cold storage preservation. Methods: From October 2008 to February 2011, 59 pairs of kidney from consecutive 18 to 79 years old donors were included in the present trial. One kidney was randomly assigned to HMP and the contralateral kidney to CS. Among the 59 kidneys enrolled in HMP group, 11 have been excluded for technical/logistic issues or renal artery unavailability. Primary endpoint was delayed graft function (DGF), secondary endpoints were DGF lenght, primary non function (PNF), serum creatinine level and clearance, acute rejection, acute tubular necrosis, length of hospital stay and allograft and patient survival. Results: No statistically significant difference was found between graft preserved by machine perfusion and cold storage in terms of DGF rate (37,8% vs 30%, respectively p>0.05). No significant differences were observed for the other secondary end points.
Conclusion:
The effectiveness of preservation with HMP in brain death donors, both ideal and marginal, appear controversial; more data need to be collected in selected donors.
